210 related articles for article (PubMed ID: 21622731)
21. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.
Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ
PLoS One; 2009 Sep; 4(9):e6967. PubMed ID: 19742314
[TBL] [Abstract][Full Text] [Related]
22. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M
Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695
[TBL] [Abstract][Full Text] [Related]
23. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
24. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.
Vidal A; Muñoz C; Guillén MJ; Moretó J; Puertas S; Martínez-Iniesta M; Figueras A; Padullés L; García-Rodriguez FJ; Berdiel-Acer M; Pujana MA; Salazar R; Gil-Martin M; Martí L; Ponce J; Molleví DG; Capella G; Condom E; Viñals F; Huertas D; Cuevas C; Esteller M; Avilés P; Villanueva A
Clin Cancer Res; 2012 Oct; 18(19):5399-411. PubMed ID: 22896654
[TBL] [Abstract][Full Text] [Related]
25. Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.
Harnicek D; Kampmann E; Lauber K; Hennel R; Cardoso Martins AS; Guo Y; Belka C; Mörtl S; Gallmeier E; Kanaar R; Mansmann U; Hucl T; Lindner LH; Hiddemann W; Issels RD
Int J Cancer; 2016 Jul; 139(2):467-79. PubMed ID: 26933761
[TBL] [Abstract][Full Text] [Related]
26. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Belgiovine C; Bello E; Liguori M; Craparotta I; Mannarino L; Paracchini L; Beltrame L; Marchini S; Galmarini CM; Mantovani A; Frapolli R; Allavena P; D'Incalci M
Br J Cancer; 2017 Aug; 117(5):628-638. PubMed ID: 28683469
[TBL] [Abstract][Full Text] [Related]
27. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
[TBL] [Abstract][Full Text] [Related]
28. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
29. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
[TBL] [Abstract][Full Text] [Related]
30. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
[TBL] [Abstract][Full Text] [Related]
31. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
32. Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma.
Pernice T; Bishop AG; Guillen MJ; Cuevas C; Aviles P
J Pharm Biomed Anal; 2016 May; 123():37-41. PubMed ID: 26871278
[TBL] [Abstract][Full Text] [Related]
33. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
34. Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells.
Mukai M; Kanzaki A; Chen ZS; Miyashita H; Sumizawa T; Furukawa T; Haraguchi M; Takebayashi Y; Takamatsu H; Akiyama S
Oncol Rep; 2002; 9(4):839-44. PubMed ID: 12066219
[TBL] [Abstract][Full Text] [Related]
35. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
Graf N; Ang WH; Zhu G; Myint M; Lippard SJ
Chembiochem; 2011 May; 12(7):1115-23. PubMed ID: 21452186
[TBL] [Abstract][Full Text] [Related]
36. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
37. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
[TBL] [Abstract][Full Text] [Related]
38. Trabectedin for the treatment of breast cancer.
D'Incalci M; Zambelli A
Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
[TBL] [Abstract][Full Text] [Related]
39. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.
Takebayashi Y; Pourquier P; Zimonjic DB; Nakayama K; Emmert S; Ueda T; Urasaki Y; Kanzaki A; Akiyama SI; Popescu N; Kraemer KH; Pommier Y
Nat Med; 2001 Aug; 7(8):961-6. PubMed ID: 11479630
[TBL] [Abstract][Full Text] [Related]
40. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.
Beumer JH; Buckle T; Ouwehand M; Franke NE; Lopez-Lazaro L; Schellens JH; Beijnen JH; van Tellingen O
Invest New Drugs; 2007 Feb; 25(1):1-7. PubMed ID: 16633714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
